Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
MTX-E1
- Development stage
- Preclinical
- Lead developer
- Montara Therapeutics
- Modality
- Small Molecules
- Administration
- Oral, Intramuscular, Intravenous, Subcutaneous, Intraarticular, Local, Intra-arterial
01
Overview
MTX-E1 is Montara Therapeutics' investigational two-small-molecule BrainOnly combination for **tuberous sclerosis complex-related epilepsy**. It combines MT1110, a peripherally restricted FK506-binding protein 12 blocker, with everolimus, an FKBP12-dependent mechanistic target of rapamycin inhibitor. MT1110 competitively occupies peripheral FKBP12 binding sites to reduce peripheral everolimus activity while preserving brain mTOR inhibition, with the goal of improving the therapeutic index of mTOR inhibition in the central nervous system. ([montaratx.com](https://montaratx.com/montara-therapeutics-announces-development-candidate-for-first-brainonly/))
- Other names
- everolimus + MT1110MT1110 + everolimusMT1110-everolimusMT-1110-everolimusMT 1110-everolimus
02
Targets
mTOR (Mammalian target of rapamycin kinase)FKBP1A
Beyond the preview
Go deeper on MTX-E1.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on MTX-E1.